| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| E J Marijke Achterberg, Linda W M van Kerkhof, Ruth Damsteegt, Viviana Trezza, Louk J M J Vanderschure. Methylphenidate and atomoxetine inhibit social play behavior through prefrontal and subcortical limbic mechanisms in rats. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 35. issue 1. 2015-03-20. PMID:25568111. |
we have previously shown that methylphenidate and atomoxetine, drugs widely used for the treatment of attention-deficit hyperactivity disorder (adhd), suppress social play in rats through a noradrenergic mechanism of action. |
2015-03-20 |
2023-08-13 |
rat |
| Thomas Vanicek, Marie Spies, Christina Rami-Mark, Markus Savli, Anna Höflich, Georg S Kranz, Andreas Hahn, Alexandra Kutzelnigg, Tatjana Traub-Weidinger, Markus Mitterhauser, Wolfgang Wadsak, Marcus Hacker, Nora D Volkow, Siegfried Kasper, Rupert Lanzenberge. The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. JAMA psychiatry. vol 71. issue 12. 2015-03-01. PMID:25338091. |
however, a case has been made for the involvement of the noradrenergic system, which modulates cognitive processes, such as arousal, working memory, and response inhibition, all of which are typically affected in adhd. |
2015-03-01 |
2023-08-13 |
Not clear |
| Ralf W Dittmann, Esther Cardo, Peter Nagy, Colleen S Anderson, Ralph Bloomfield, Beatriz Caballero, Nicholas Higgins, Paul Hodgkins, Andrew Lyne, Richard Civil, David Coghil. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS drugs. vol 27. issue 12. 2014-08-26. PMID:23959815. |
the aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (ldx) and the non-stimulant noradrenergic compound atomoxetine (atx) in children and adolescents with attention-deficit/hyperactivity disorder (adhd) who had previously responded inadequately to methylphenidate (mph). |
2014-08-26 |
2023-08-12 |
Not clear |
| A Bari, T W Robbin. Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to ADHD. Psychopharmacology. vol 230. issue 1. 2014-06-10. PMID:23681165. |
noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task: possible relevance to adhd. |
2014-06-10 |
2023-08-12 |
rat |
| Nina D Shiffrin, June Gruber, Stephen J Glatt, Stephen V Faraon. No association between MspI allele of the ADRA2A polymorphism and ADHD: meta-analysis of family-based studies. Psychiatric genetics. vol 23. issue 4. 2014-04-25. PMID:23751900. |
given that the noradrenergic system has been implicated in adhd, the gene for the α2-adrenergic receptor (adra2a) has been hypothesized to contribute to the pathogenesis of adhd. |
2014-04-25 |
2023-08-12 |
Not clear |
| Samuel R Chamberlain, Trevor W Robbin. Noradrenergic modulation of cognition: therapeutic implications. Journal of psychopharmacology (Oxford, England). vol 27. issue 8. 2014-01-30. PMID:23518815. |
remarkable parallels across species have been reported which may account for the mechanisms by which noradrenergic medications exert their beneficial effects in disorders such as depression and attention-deficit hyperactivity disorder (adhd). |
2014-01-30 |
2023-08-12 |
human |
| Bung-Nyun Kim, Jae-Won Kim, Tarrant D R Cummins, Mark A Bellgrove, Ziarih Hawi, Soon-Beom Hong, Young-Hui Yang, Hyo-Jin Kim, Min-Sup Shin, Soo-Churl Cho, Ji-Hoon Kim, Jung-Woo Son, Yun-Mi Shin, Un-Sun Chung, Doug-Hyun Ha. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder. Journal of clinical psychopharmacology. vol 33. issue 3. 2013-11-07. PMID:23609393. |
noradrenergic dysfunction may be associated with cognitive impairments in attention-deficit/hyperactivity disorder (adhd), including increased response time variability, which has been proposed as a leading endophenotype for adhd. |
2013-11-07 |
2023-08-12 |
human |
| Ozan Pazvantoğlu, Sezgin Güneş, Koray Karabekiroğlu, Zeynep Yeğin, Zehra Erenkuş, Seher Akbaş, Gökhan Sarısoy, Işıl Zabun Korkmaz, Omer Böke, Hasan Bağcı, Ahmet Rifat Sahi. The relationship between the presence of ADHD and certain candidate gene polymorphisms in a Turkish sample. Gene. vol 528. issue 2. 2013-11-05. PMID:23872233. |
problems associated with the noradrenergic and serotonergic systems and snap-25 may play a role, both alone and in interaction with one another, in the pathophysiological mechanisms of adhd. |
2013-11-05 |
2023-08-12 |
Not clear |
| Ziarih Hawi, Natasha Matthews, Edwina Barry, Aiveen Kirley, Joseph Wagner, Robyn H Wallace, Helen S Heussler, Alasdair Vance, Michael Gill, Mark A Bellgrov. A high density linkage disequilibrium mapping in 14 noradrenergic genes: evidence of association between SLC6A2, ADRA1B and ADHD. Psychopharmacology. vol 225. issue 4. 2013-10-17. PMID:23052569. |
a high density linkage disequilibrium mapping in 14 noradrenergic genes: evidence of association between slc6a2, adra1b and adhd. |
2013-10-17 |
2023-08-12 |
Not clear |
| Ziarih Hawi, Natasha Matthews, Edwina Barry, Aiveen Kirley, Joseph Wagner, Robyn H Wallace, Helen S Heussler, Alasdair Vance, Michael Gill, Mark A Bellgrov. A high density linkage disequilibrium mapping in 14 noradrenergic genes: evidence of association between SLC6A2, ADRA1B and ADHD. Psychopharmacology. vol 225. issue 4. 2013-10-17. PMID:23052569. |
pharmacological evidence suggests the importance of noradrenergic and other monoaminergic neurotransmitters in the aetiology and treatment of attention deficit hyperactivity disorder (adhd). |
2013-10-17 |
2023-08-12 |
Not clear |
| Ziarih Hawi, Natasha Matthews, Edwina Barry, Aiveen Kirley, Joseph Wagner, Robyn H Wallace, Helen S Heussler, Alasdair Vance, Michael Gill, Mark A Bellgrov. A high density linkage disequilibrium mapping in 14 noradrenergic genes: evidence of association between SLC6A2, ADRA1B and ADHD. Psychopharmacology. vol 225. issue 4. 2013-10-17. PMID:23052569. |
until recently, the genes of the noradrenergic pathway were not intensively investigated in adhd compared to dopaminergic and serotonergic candidates. |
2013-10-17 |
2023-08-12 |
Not clear |
| Ziarih Hawi, Natasha Matthews, Edwina Barry, Aiveen Kirley, Joseph Wagner, Robyn H Wallace, Helen S Heussler, Alasdair Vance, Michael Gill, Mark A Bellgrov. A high density linkage disequilibrium mapping in 14 noradrenergic genes: evidence of association between SLC6A2, ADRA1B and ADHD. Psychopharmacology. vol 225. issue 4. 2013-10-17. PMID:23052569. |
in this study, 91 snp markers of 14 noradrenergic genes (an average density of one snp per 4.5 kbp) were examined in adhd samples from ireland and australia. |
2013-10-17 |
2023-08-12 |
Not clear |
| Laura S Visen. [Attention deficit hyperactivity disorder (ADHD): an overview]. Vertex (Buenos Aires, Argentina). vol 23. issue 105. 2013-09-05. PMID:23269966. |
pharmacological treatment approaches for adhd as well as for some of the psychiatry comorbidities involve the dopaminergic, noradrenergic and serotoninergic systems. |
2013-09-05 |
2023-08-12 |
Not clear |
| Subin Park, Jae-Won Kim, Young-Hui Yang, Soon-Beom Hong, Min-Hyeon Park, Boong-Nyun Kim, Min-Sup Shin, Hee-Jeong Yoo, Soo-Churl Ch. Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder. Behavioral and brain functions : BBF. vol 8. 2013-04-23. PMID:22591463. |
dysregulation of noradrenergic system may play important roles in pathophysiology of attention-deficit/hyperactivity disorder (adhd). |
2013-04-23 |
2023-08-12 |
Not clear |
| Seyed Khosrow Tayebati, Daniele Tomassoni, Francesco Ament. Spontaneously hypertensive rat as a model of vascular brain disorder: microanatomy, neurochemistry and behavior. Journal of the neurological sciences. vol 322. issue 1-2. 2013-04-11. PMID:22726353. |
shr are also characterized by a dopaminergic hypofunction and noradrenergic hyperactivity similarly as occurs in attention-deficit with hyperactivity disorder (adhd). |
2013-04-11 |
2023-08-12 |
human |
| Emrah Cayla. Biochemical and genetic analyses of childhood attention deficit/hyperactivity disorder. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 159B. issue 6. 2013-04-09. PMID:22825876. |
to date, these studies have reported substantial evidence implicating several genes (dopaminergic: drd4, dat1, drd5, comt; noradrenergic: dbh, adra2a; serotonergic: 5-htt, htr1b, htr2a; cholinergic: chrna4, and central nervous system development pathway: snap25, bdnf) in the etiology of adhd. |
2013-04-09 |
2023-08-12 |
Not clear |
| Adel E El-Tarras, Adnan A Alsulaimani, Nabil S Awad, Nahla Mitwaly, Manal M Said, Ayman M Sabr. Association study between the dopamine-related candidate gene polymorphisms and ADHD among Saudi Arabia population via PCR technique. Molecular biology reports. vol 39. issue 12. 2013-04-04. PMID:23076524. |
there are several evidences for involvement of dopaminergic, serotonergic and noradrenergic neurotransmitter systems in the pathogenesis of adhd. |
2013-04-04 |
2023-08-12 |
human |
| Oscar Gary Bukstein, Jared Hea. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder. Expert opinion on pharmacotherapy. vol 13. issue 15. 2013-01-29. PMID:22957772. |
guanfacine extended release (gxr) is an alpha 1a noradrenergic agonist that has been approved by the fda for the treatment of attention-deficit/hyperactivity disorder (adhd) as a monotherapy, and as an adjunctive therapy to stimulants for the treatment of adhd in children and adolescents age 6 - 17. |
2013-01-29 |
2023-08-12 |
Not clear |
| Terje Sagvolden, Tong X. l-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD). Behavioral and brain functions : BBF. vol 4. 2012-10-02. PMID:18215285. |
there is no biological marker, but there is considerable evidence to suggest that adhd behavior is associated with poor dopaminergic and noradrenergic modulation of neuronal circuits that involve the frontal lobes. |
2012-10-02 |
2023-08-12 |
rat |
| Fleur M Howells, Leander Bindewald, Vivienne A Russel. Cross-fostering does not alter the neurochemistry or behavior of spontaneously hypertensive rats. Behavioral and brain functions : BBF. vol 5. 2012-10-02. PMID:19549323. |
the most widely used animal model, the spontaneously hypertensive rat (shr), displays the major symptoms of adhd (deficits in attention, impulsivity and hyperactivity) and has a disturbance in the noradrenergic system when compared to control wistar-kyoto rats (wky). |
2012-10-02 |
2023-08-12 |
rat |